blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3320904

EP3320904 - PREVENTATIVE AND/OR THERAPEUTIC AGENT CONTAINING PYRIDYL AMINOACETIC ACID COMPOUND FOR TREATING A DISEASE INVOLVING A GREATLY ELEVATED INTRAOCULAR PRESSURE [Right-click to bookmark this link]
Former [2018/20]PREVENTATIVE AND/OR THERAPEUTIC AGENT CONTAINING PYRIDYL AMINOACETIC ACID COMPOUND
[2023/08]
StatusNo opposition filed within time limit
Status updated on  10.05.2024
Database last updated on 18.11.2024
FormerThe patent has been granted
Status updated on  02.06.2023
FormerGrant of patent is intended
Status updated on  25.01.2023
FormerExamination is in progress
Status updated on  03.01.2020
FormerRequest for examination was made
Status updated on  13.04.2018
FormerThe international publication has been made
Status updated on  13.01.2017
Most recent event   Tooltip15.11.2024Lapse of the patent in a contracting state
New state(s): BG		published on 18.12.2024 [2024/51]
Applicant(s)For all designated states
Santen Pharmaceutical Co., Ltd.
4-20, Ofuka-cho
Kita-ku
Osaka-shi
Osaka 530-8552 / JP
[2023/22]
Former [2018/20]For all designated states
Santen Pharmaceutical Co., Ltd.
9-19, Shimoshinjo 3-chome
Higashiyodogawa-ku
Osaka-shi
Osaka 533-8651 / JP
Inventor(s)01 / KIRIHARA, Tomoko
c/o SANTEN PHARMACEUTICAL CO. LTD.
8916-16 Takayama-cho
Ikoma-shi Nara 630-0101 / JP
02 / SHIMAZAKI, Atsushi
c/o SANTEN PHARMACEUTICAL CO. LTD.
4-20 Ofuka-cho
Kita-ku
Osaka-shi Osaka 530-8552 / JP
03 / SHARIF, Najam A.
6401 Hollis Street
Suite 125
Emeryville, California 94608 / US
 [2018/20]
Representative(s)Müller-Boré & Partner Patentanwälte PartG mbB
Friedenheimer Brücke 21
80639 München / DE
[2018/20]
Application number, filing date16821453.407.07.2016
[2018/20]
WO2016JP70110
Priority number, dateJP2015013796809.07.2015         Original published format: JP 2015137968
[2018/20]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017006985
Date:12.01.2017
Language:JA
[2017/02]
Type: A1 Application with search report 
No.:EP3320904
Date:16.05.2018
Language:EN
[2018/20]
Type: B1 Patent specification 
No.:EP3320904
Date:05.07.2023
Language:EN
[2023/27]
Search report(s)International search report - published on:JP12.01.2017
(Supplementary) European search report - dispatched on:EP02.07.2018
ClassificationIPC:A61K31/444, A61P27/02, A61P27/06
[2018/20]
CPC:
A61K31/444 (EP,US); A61K9/0048 (US); A61P27/02 (EP,US);
A61P27/06 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/20]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:PRÄVENTIVER UND/ODER THERAPEUTISCHER WIRKSTOFF MIT PYRIDYL-AMINOESSIGSÄURE-VERBINDUNG ZUR BEHANDLUNG EINER KRANKHEIT MIT EINEM STARK ERHÖHTEN INNENAUGENDRUCK[2023/08]
English:PREVENTATIVE AND/OR THERAPEUTIC AGENT CONTAINING PYRIDYL AMINOACETIC ACID COMPOUND FOR TREATING A DISEASE INVOLVING A GREATLY ELEVATED INTRAOCULAR PRESSURE[2023/08]
French:AGENT PRÉVENTIF ET/OU THÉRAPEUTIQUE CONTENANT UN COMPOSÉ D'ACIDE AMINOACÉTIQUE PYRIDYLE POUR TRAITER UNE MALADIE IMPLIQUANT UNE PRESSION INTRAOCULAIRE TRÈS ÉLEVÉE[2023/08]
Former [2018/20]PRÄVENTIVER UND/ODER THERAPEUTISCHER WIRKSTOFF MIT PYRIDYL-AMINOESSIGSÄURE-VERBINDUNG
Former [2018/20]PREVENTATIVE AND/OR THERAPEUTIC AGENT CONTAINING PYRIDYL AMINOACETIC ACID COMPOUND
Former [2018/20]AGENT PRÉVENTIF ET/OU THÉRAPEUTIQUE CONTENANT UN COMPOSÉ D'ACIDE AMINOACÉTIQUE PYRIDYLE
Entry into regional phase24.01.2018Translation filed 
25.01.2018National basic fee paid 
25.01.2018Search fee paid 
25.01.2018Designation fee(s) paid 
25.01.2018Examination fee paid 
Examination procedure24.01.2018Date on which the examining division has become responsible
25.01.2018Examination requested  [2018/20]
11.01.2019Amendment by applicant (claims and/or description)
08.01.2020Despatch of a communication from the examining division (Time limit: M04)
06.05.2020Reply to a communication from the examining division
17.12.2020Despatch of a communication from the examining division (Time limit: M04)
18.03.2021Reply to a communication from the examining division
26.07.2021Despatch of a communication from the examining division (Time limit: M04)
15.10.2021Reply to a communication from the examining division
13.01.2023Cancellation of oral proceeding that was planned for 18.01.2023
18.01.2023Date of oral proceedings (cancelled)
26.01.2023Communication of intention to grant the patent
19.05.2023Receipt of the translation of the claim(s)
25.05.2023Fee for grant paid
25.05.2023Fee for publishing/printing paid
Opposition(s)08.04.2024No opposition filed within time limit [2024/24]
Fees paidRenewal fee
23.07.2018Renewal fee patent year 03
26.07.2019Renewal fee patent year 04
23.07.2020Renewal fee patent year 05
26.07.2021Renewal fee patent year 06
27.07.2022Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT05.07.2023
BG05.07.2023
CZ05.07.2023
DK05.07.2023
EE05.07.2023
FI05.07.2023
HR05.07.2023
LT05.07.2023
LV05.07.2023
MC05.07.2023
NL05.07.2023
PL05.07.2023
RO05.07.2023
RS05.07.2023
SE05.07.2023
SI05.07.2023
SK05.07.2023
SM05.07.2023
IE07.07.2023
LU07.07.2023
BE31.07.2023
CH31.07.2023
NO05.10.2023
GR06.10.2023
IS05.11.2023
PT06.11.2023
[2024/51]
Former [2024/36]AT05.07.2023
CZ05.07.2023
DK05.07.2023
EE05.07.2023
FI05.07.2023
HR05.07.2023
LT05.07.2023
LV05.07.2023
MC05.07.2023
NL05.07.2023
PL05.07.2023
RO05.07.2023
RS05.07.2023
SE05.07.2023
SI05.07.2023
SK05.07.2023
SM05.07.2023
IE07.07.2023
LU07.07.2023
BE31.07.2023
CH31.07.2023
NO05.10.2023
GR06.10.2023
IS05.11.2023
PT06.11.2023
Former [2024/33]AT05.07.2023
CZ05.07.2023
DK05.07.2023
EE05.07.2023
FI05.07.2023
HR05.07.2023
LT05.07.2023
LV05.07.2023
MC05.07.2023
NL05.07.2023
PL05.07.2023
RO05.07.2023
RS05.07.2023
SE05.07.2023
SK05.07.2023
SM05.07.2023
IE07.07.2023
LU07.07.2023
BE31.07.2023
CH31.07.2023
NO05.10.2023
GR06.10.2023
IS05.11.2023
PT06.11.2023
Former [2024/23]AT05.07.2023
CZ05.07.2023
DK05.07.2023
EE05.07.2023
FI05.07.2023
HR05.07.2023
LT05.07.2023
LV05.07.2023
MC05.07.2023
NL05.07.2023
PL05.07.2023
RO05.07.2023
RS05.07.2023
SE05.07.2023
SK05.07.2023
SM05.07.2023
LU07.07.2023
BE31.07.2023
CH31.07.2023
NO05.10.2023
GR06.10.2023
IS05.11.2023
PT06.11.2023
Former [2024/22]AT05.07.2023
CZ05.07.2023
DK05.07.2023
FI05.07.2023
HR05.07.2023
LT05.07.2023
LV05.07.2023
NL05.07.2023
PL05.07.2023
RO05.07.2023
RS05.07.2023
SE05.07.2023
SM05.07.2023
LU07.07.2023
NO05.10.2023
GR06.10.2023
IS05.11.2023
PT06.11.2023
Former [2024/20]AT05.07.2023
FI05.07.2023
HR05.07.2023
LT05.07.2023
LV05.07.2023
NL05.07.2023
PL05.07.2023
RS05.07.2023
SE05.07.2023
SM05.07.2023
LU07.07.2023
NO05.10.2023
GR06.10.2023
IS05.11.2023
PT06.11.2023
Former [2024/18]AT05.07.2023
FI05.07.2023
HR05.07.2023
LT05.07.2023
LV05.07.2023
NL05.07.2023
PL05.07.2023
RS05.07.2023
SE05.07.2023
LU07.07.2023
NO05.10.2023
GR06.10.2023
IS05.11.2023
PT06.11.2023
Former [2024/10]AT05.07.2023
FI05.07.2023
HR05.07.2023
LT05.07.2023
LV05.07.2023
NL05.07.2023
PL05.07.2023
RS05.07.2023
SE05.07.2023
NO05.10.2023
GR06.10.2023
IS05.11.2023
PT06.11.2023
Former [2024/09]AT05.07.2023
FI05.07.2023
LT05.07.2023
NL05.07.2023
SE05.07.2023
NO05.10.2023
GR06.10.2023
IS05.11.2023
Former [2024/08]LT05.07.2023
NL05.07.2023
NO05.10.2023
GR06.10.2023
Former [2024/05]NL05.07.2023
Documents cited:Search[E]EP3093018  (SANTEN PHARMACEUTICAL CO LTD [JP]) [E] 1-8* the whole document *
International search[XY]WO2010113957  (UBE INDUSTRIES [JP], et al) [X] 1, 3-9, 11-18 * , claims 1, 18; paragraphs [0010], [0194], [0285] & US 2012/0190852 A1 claims 1, 18; paragraphs [0058], [0689], [0895] * [Y] 2, 10;
 [XY]US2014018396  (KIRIHARA TOMOKO [JP], et al) [X] 1-18 * , claim 1; paragraphs [0023], [0025], [0044], [0081], [0091], [0110], [0130] (Family: none) * [Y] 2, 10;
 [XY]JP2014019650  (SANTEN PHARMACEUTICAL CO LTD , et al) [X] 1-18 * , claim 1; paragraphs [0024], [0026], [0045], [0075] (Family: none) * [Y] 2, 10;
 [XY]JP2014031369  (SANTEN PHARMACEUTICAL CO LTD ) [X] 1-18 * , claim 1; paragraphs [0024], [0026], [0045], [0091], [0127], [0145] (Family: none) * [Y] 2, 10;
 [A]  - IHEKOROMADU et al., "Safety and Efficacy of DE 117, a Selective EP 2 Agonist in a Phase 2a Study", Investigative Ophthalmology & Visual Science, (20150600), vol. 56, no. Issue 7, page 5708, XP009504322 [A] 1-18 * , ARVO Annual Meeting Abstract *
Examination   - JOST B. JONAS ET AL, "Ocular Hypertension: General Characteristics and Estimated Cerebrospinal Fluid Pressure. The Beijing Eye Study 2011", PLOS ONE, (20140702), vol. 9, no. 7, doi:10.1371/journal.pone.0100533, page e100533, XP055759317

DOI:   http://dx.doi.org/10.1371/journal.pone.0100533
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.